Could Menopause Timing and Hormone Therapy Affect Alzheimer’s Risk?

In this edition of What We’re Reading, we’re looking at a recent Scientific American article that explores an important question in women’s health: Could the timing of menopause—and possibly the timing of hormone therapy—play a role in a woman’s long-term risk of cognitive decline and Alzheimer’s disease?

The August 26, 2026 article, “Is There a ‘Window of Opportunity’ to Prevent Alzheimer’s in Women?”, highlights two newly published studies examining the relationship between menopause, hormone exposure, brain aging, and dementia.

The findings do not establish that hormone therapy prevents Alzheimer’s disease. But they add to a growing body of research suggesting that the menopause transition may be an important period for understanding women’s brain health—and that when menopause occurs may matter decades later.

Hormone Therapy and Dementia Risk

One of the studies, published in Alzheimer’s & Dementia, analyzed data from more than 180,000 postmenopausal women in the United Kingdom over approximately 13 years.

Researchers found that women who had used hormone replacement therapy, or HRT, had a 10% lower risk of dementia overall and a 16% lower risk of Alzheimer’s disease compared with women who had not used HRT. The association was more pronounced among women who had experienced surgical menopause, with a reported 26% lower dementia risk in that group. Women who began HRT between ages 46 and 56 also had lower dementia risk than those who started treatment later in life.

These results are noteworthy, but they should be interpreted with care. This was an observational study, meaning researchers examined patterns in real-world health data rather than randomly assigning women to receive hormone therapy or not. That means the study can identify an association, but it cannot prove that HRT itself prevented dementia or Alzheimer’s disease.

Earlier Menopause and Long-Term Brain Health

A second study, published August 25 in JAMA Network Open, followed 2,603 older women and examined age at menopause in relation to cognitive decline, Alzheimer’s diagnosis, and changes in brain structure.

Researchers found that an earlier age at menopause was associated with faster decline in overall cognition and episodic memory, as well as an earlier diagnosis of Alzheimer’s disease.

The study also identified measurable differences in the brain. Among women who experienced spontaneous menopause, earlier menopause was associated with faster accumulation of white matter hyperintensities, the areas visible on MRI that can reflect changes or damage in the brain’s white matter.

Importantly, these associations could still be detected decades after menopause.

Researchers described age at menopause as a potentially useful midlife marker that could someday help identify women who may benefit from earlier attention to factors associated with healthy brain aging.

The findings were particularly notable among women who had experienced surgical menopause, although the relationships varied depending on the cognitive or structural outcome researchers examined.

What These Studies Do and Don’t Show

The findings are encouraging, but they should be interpreted carefully.

Neither study proves that hormone therapy prevents Alzheimer’s disease or dementia. The HRT study was observational, meaning researchers identified associations in health data rather than randomly assigning participants to take hormone therapy or not. As a result, the research cannot establish cause and effect.

Hormone therapy is also not the same for every woman. Its potential benefits and risks can vary based on factors such as:

• Age and time since menopause
• Whether menopause happened naturally or followed removal of the ovaries
• Whether the uterus is present
• The type, dose, and route of hormone therapy
• Personal and family history of conditions such as breast cancer, blood clots, stroke, heart disease, or liver disease
• Individual symptoms, risk factors, and health goals

Previous research has shown mixed results, particularly when combined hormone therapy was started in women age 65 or older. That is why experts caution against viewing HRT as a proven dementia-prevention treatment at this time. More well-designed clinical trials are needed to clarify who may benefit, which formulations matter most, and when treatment may be most appropriate.

From Our Perspective

At Nore Women’s Health, we find this research important for a larger reason: menopause is not simply about managing hot flashes.

The hormonal transition that occurs during perimenopause and menopause affects multiple systems throughout the body, including the brain. Research increasingly reinforces the value of looking at menopause as part of a woman’s overall midlife and long-term health.

These studies also highlight why a woman’s menopause history matters. The age at which menopause begins, whether it occurs naturally or after removal of the ovaries, the severity of symptoms, and a woman’s individual health history can all provide valuable context when discussing care.

For women who experience early menopause or surgical menopause, in particular, these findings offer another reason to have a thoughtful conversation with a healthcare provider about the potential health implications of earlier loss of ovarian hormone production.

At the same time, we want to be careful about what this research does—and does not—tell us.

Hormone therapy is not currently recommended as a treatment to prevent Alzheimer’s disease or dementia. These studies are encouraging researchers to investigate whether timing, formulation, menopause type, and other individual factors may help explain why previous studies of hormone therapy and cognitive health have produced different results.

That distinction is important. Hormone therapy should be considered based on each woman’s symptoms, medical history, risk factors, stage of menopause, and personal goals—not because of a promise that it will prevent dementia.

What we find particularly encouraging is the growing recognition that women’s health in midlife deserves greater attention. Menopause may represent an important opportunity to evaluate not only symptoms, but also cardiovascular health, bone health, sleep, metabolic health, emotional well-being, and other factors that contribute to healthy aging.

If you are experiencing menopause symptoms, entered menopause earlier than expected, have undergone removal of the ovaries, or are wondering whether hormone therapy may be appropriate for you, a personalized conversation with a women’s health provider can help you understand your options.

The research into menopause and brain health is still evolving. But one message is becoming increasingly clear: what happens during midlife may matter to women’s health for decades to come.

Read the Full Article

 

📖 Is There a “Window of Opportunity” to Prevent Alzheimer’s in Women?
Scientific American
The article examines how the timing of menopause and hormone therapy may be linked with cognitive decline and dementia risk. Read the article from Scientific American.

📖 Age at Menopause and Brain Atrophy Among Older Women
JAMA Network Open
Published August 25, 2026.
Read the study

This article is intended for educational purposes and is not a substitute for personalized medical advice. Please speak with a qualified healthcare provider before starting, stopping, or changing hormone therapy.

~~~

At Nore Health, we’re committed to sharing trusted resources and evidence-based information that empowers women to make informed decisions about their health.